Quick Facts

• Supports the reduction of intraocular pressure (IOP).
• Used for patients managing open-angle glaucoma.
• Indicated for individuals with ocular hypertension.
• Intended for use when a single medication provides insufficient IOP reduction.

---

Alcon Azarga is indicated for use in adult patients who require a reduction in elevated intraocular pressure (IOP). This medication is an available treatment option for individuals diagnosed with either open-angle glaucoma or ocular hypertension. Ocular hypertension involves pressure inside the eye that is higher than the established normal range, and open-angle glaucoma is a condition characterized by pressure elevation often associated with impaired fluid drainage. Both conditions represent risk factors for potential damage to the optic nerve. Azarga may be recommended when therapeutic regimens involving a single active ingredient have not provided a sufficient reduction in IOP. The purpose of this medication is to help maintain IOP levels within a suitable range for the patient.

Regulatory References

1. European Medicines Agency (EMA) therapeutic overview

Azarga (brinzolamide/timolol) is officially indicated for use in adult patients with open-angle glaucoma or ocular hypertension. However, due to its components, regulatory labeling defines several strict exclusions and restrictions on its use.

Eligibility and Exclusion Status

Category	Regulatory Status	Practical Implication
Pediatric Use (Below 18 years)	Not Recommended	Safety and efficacy have not been established in children and adolescents.
Pregnancy and Lactation	Use Highly Restricted/Prohibited	Should not be used during pregnancy unless clearly necessary; do not use while breastfeeding due to timolol excretion in milk.
Contraindicated Conditions	Absolute Prohibition	Must not be used in patients with bronchial asthma (or history), severe COPD, certain cardiac conditions (e.g., overt cardiac failure, sinus bradycardia), severe renal impairment (CrCl < 30 mL/min), or hyperchloraemic acidosis.
Hypersensitivity	Absolute Prohibition	Contraindicated for patients with known allergy to the active substances, other beta-blockers, or sulphonamides (sulfa-containing medicines).
Use with Caution	Conditional Use	Caution is advised in patients with severe hepatic impairment, corneal diseases, diabetes mellitus, or first-degree heart block; close monitoring is recommended for these groups.

The official interaction profile for Azarga is structured around the potential for systemic exposure and additive pharmacodynamic effects resulting from the absorption of the active ingredients, Brinzolamide and Timolol, into the bloodstream.

Interaction-Related Restrictions and Constraints

• Contraindicated Topical Combinations: The use of two topical beta-adrenergic blocking agents or two local carbonic anhydrase inhibitors is formally not recommended due to the potential for compounded systemic effects.
• Additive Systemic Effects: Co-administration with agents such as systemic beta-blocking agents, oral calcium channel blockers, antiarrhythmics, or digitalis glycosides may result in additive effects on the cardiovascular system, including the potentiation of systemic beta-blockade.
• Metabolism Inhibition: Inhibitors of CYP3A4 (e.g., ketoconazole, ritonavir) and CYP2D6 (e.g., quinidine, fluoxetine) are documented to interfere with the metabolism of the active ingredients, which is expected to increase systemic exposure. Caution is advised when these are co-administered.
• Ophthalmic Administration Timing: If a patient is using other topical ophthalmic medicinal products, they must be administered at least five minutes apart from Azarga to prevent wash-out and ensure proper effect.
• Population Note: The potential for acid-base alterations should be considered when co-administering with High-Dose Salicylate Therapy.

How Alcon Azarga Works

Dual Blockade of Aqueous Fluid Production

The combination's action involves a dual-pathway mechanism that suppresses the formation of the eye's internal fluid, known as aqueous humor. By targeting two distinct molecular systems, the combination exerts a substantial, combined effect that limits the volume of fluid produced and secreted by the ciliary body epithelium . This simultaneous disruption of fluid supply results in a decrease in the pressure-driving component of the fluid dynamic inside the eye.

Enzyme Inhibition and Receptor Antagonism

The suppression of fluid production relies on two separate mechanistic domains. Brinzolamide acts as an enzyme inhibitor, blocking Carbonic Anhydrase II (CA-II) to disrupt the formation of essential solutes (like bicarbonate) needed to drive fluid transport. Concurrently, Timolol operates via receptor antagonism, blocking beta-adrenergic receptors to modulate the autonomic signaling that stimulates the secretory activity of the ciliary cells. The mechanism engages both the metabolic (enzyme-driven) and the neural (receptor-driven) regulation of fluid secretion.

Administration Protocol

Alcon Azarga is administered solely via topical ophthalmic instillation (eye drops). The standard dose for adults, including older adults, is one drop into the conjunctival sac of the affected eye(s) twice daily (e.g., morning and evening), and this frequency should not be exceeded.

Procedural Instructions

Before administration, the bottle must be shaken well to ensure the suspension is uniform. To minimize systemic absorption, nasolacrimal occlusion (applying gentle pressure to the inner corner of the eye) or closing the eyelid for two minutes after instillation is recommended.

If a dose is missed, the treatment should continue with the next scheduled dose; doubling the dose is not permitted. When substituting Azarga for another eye drop, the previous agent should be discontinued, and Azarga should be started the subsequent day.

Constraints and Special Populations

Specific procedural constraints apply to prevent contamination and potential effects on the eye. If more than one topical ophthalmic medicine is being used, they must be administered at least 5 minutes apart, with any eye ointments applied last. Soft contact lenses must be removed prior to application, and patients must wait 15 minutes before reinsertion. Azarga is not recommended for use in children and adolescents below 18 years due to a lack of safety and efficacy data, nor is it recommended for patients with severe renal impairment (creatinine clearance <30 mL/min).

Research Evidence / Overview of Studies for Alcon Azarga

Evidence for Use in Open-Angle Glaucoma (OAG)

Research exploring this medication was evaluated in adults diagnosed with open-angle glaucoma (OAG). The primary evidence base includes several large, randomized controlled trials (RCTs) which research examined measurements of intraocular pressure (IOP) over defined time intervals. These studies often involved comparing the fixed combination to one of its individual components or included another fixed-combination eye drop as a comparator. The outcomes monitoring physiological strain or stress focused largely on measuring the mean change in IOP at different times throughout the day during the study period.

The clinical trials reported how symptoms evolved in the observed populations over intermediate periods, typically up to six months. Findings describe patterns observed in the studies regarding intraocular pressure measurements when compared to the measurements achieved by the single components. These results apply only to the populations studied and contribute to the broader evidence landscape for this condition.

Evidence for Use in Ocular Hypertension (OHT)

The structure of the research for ocular hypertension (OHT) is similar to the research conducted for OAG, focusing on adults with conditions marked by functional limitations related to elevated IOP. Pivotal trials was evaluated in this patient group. Studies monitored the outcomes related to systemic or functional imbalance by tracking the absolute level of IOP and the percentage of patients who reached a predefined target pressure measurement.

Studies examined IOP measurements when compared to its individual component drugs and data show patterns related to the pressure measurements achieved by the fixed combination over the observed time intervals. Comparative evidence is lacking for certain fixed combinations, and the existing research provides limited insight into its use in younger patient groups, as trials focused primarily on adults.

Gaps and Areas of Uncertainty in the Research Record

The research predominantly explores the physical biomarker of IOP. As a result, the existing evidence is limited regarding other outcomes reflecting daily functioning or activity level or long-term structural measures of the optic nerve.

Follow-up durations were limited in many key studies. There is limited information for long-term outcomes that track the durability of the reported pressure measurements over multiple years (e.g., five years or more). Finally, research provides context but not individual predictions regarding whether an individual will respond similarly due to variations in patient biology.

Common questions about Alcon Azarga (FAQ)

---

Q: Is it OK to use Azarga while pregnant or breastfeeding?

A: According to official regulatory documents, Azarga is not generally recommended during pregnancy unless a clear necessity is determined by a healthcare provider. Regulatory labeling indicates that use is restricted during breastfeeding, as studies show the timolol component is excreted into human milk.

Q: What should I do if I miss a dose of Azarga?

A: If a dose of the eye drops is missed, the official protocol advises that treatment should continue with the next scheduled dose as planned. It is specifically advised that doubling the dose to compensate for the missed one is not permitted.

Q: Can Azarga be used in children?

A: Official product information states that Azarga is not recommended for use in children and adolescents below 18 years of age. This restriction is based on the lack of established safety and effectiveness data in this patient population.

Q: What is the expiration date once the Azarga bottle is opened?

A: To help maintain the product's sterility, regulatory information specifies that the eye drops should be discarded four weeks (or 28 days) after the bottle is first opened. This required discard date is separate from the unopened product's labeled expiration date.

Q: Can Azarga cause a feeling of a lump in the throat?

A: The official safety documentation lists side effects such as throat irritation and pain. While a specific 'lump in the throat' sensation is not explicitly documented, the label does list related symptoms affecting the pharyngeal area.

Q: Is Azarga safe to use if I have severe dry eye disease?

A: Official product information advises caution in patients with pre-existing dry eyes or conditions affecting the cornea (the eye's clear front surface). This is because the formulation contains benzalkonium chloride, a preservative that is noted for potentially causing eye irritation or affecting the cornea.

Q: What are the components/ingredients of the eye drops (other than the active ones)?

A: The active ingredients are Brinzolamide and Timolol. Official product monographs also list inactive ingredients (called excipients) which typically include the preservative benzalkonium chloride, mannitol, carbomer 974P, tyloxapol, disodium edetate, sodium chloride, and purified water.

Storage and Disposal Requirements for Azarga

Official regulatory information specifies strict conditions for storing Azarga (brinzolamide/timolol) ophthalmic suspension to maintain its quality and sterility.

Storage Conditions

Condition	Regulatory Requirement
Temperature	Store between 2 C and 30 C.
Freezing	Do not freeze the ophthalmic suspension.
Container	Keep the bottle tightly closed when not in use.
Child Safety	Store the medicine out of the reach and sight of children.

Stability and Disposal

The suspension must be shaken well before each use. Once the bottle is opened, the eye drops must be discarded after four weeks (or 60 days, depending on the regulatory label) to ensure sterility. Unused or expired Azarga must not be disposed of in wastewater or household garbage. Instead, it should be returned to a pharmacist or collected via an authorized medicine take-back program for proper disposal, as there are no special requirements for disposal as pharmaceutical waste.